Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC-Reference-Cited by-同舟云学术

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Published:2018-08-10 Issue:1 Volume:9 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Arasada Rajeswara Rao,Shilo Konstantin,Yamada Tadaaki,Zhang Jianying,Yano Seiji,Ghanem Rashelle,Wang Walter^ORCID,Takeuchi Shinji,Fukuda Koji,Katakami Nobuyuki,Tomii Keisuke,Ogushi Fumitaka,Nishioka Yasuhiko,Talabere Tiffany,Misra Shrilekha,Duan Wenrui,Fadda Paolo,Rahman Mohammad A.,Nana-Sinkam Patrick,Evans Jason,Amann Joseph,Tchekneva Elena E.,Dikov Mikhail M.,Carbone David P.

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-018-05626-2.pdf

Reference65 articles.

1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 65, 5–29 (2015).

2. Li, T., Kung, H. J., Mack, P. C. & Gandara, D. R. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J. Clin. Oncol. 31, 1039–1049 (2013).

3. Wang, Y., Schmid-Bindert, G. & Zhou, C. Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians. Ther. Adv. Med. Oncol. 4, 19–29 (2012).

4. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).

5. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of Wnt/β-catenin pathway in cancer drug resistance: Insights into molecular aspects of major solid tumors;Biochemical and Biophysical Research Communications;2024-10

2. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities;Nature Reviews Cancer;2024-09-02

3. Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer;Lung Cancer;2024-08

4. AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells;Cancer Letters;2024-04

5. Cepharanthine suppresses APC-mutant colorectal cancers by down-regulating the expression of β-catenin;Natural Products and Bioprospecting;2024-02-29